Supportive Care

Cancer and its treatments affect sexuality, but this is not typically discussed with patients. Patients with cancer are often not forthcoming about sexuality, and nurses and other healthcare practitioners may not be comfortable raising the issue. Read More ›

aginal dehydroepiandrosterone (DHEA) may improve sexual function, without negative systemic effects, in women with breast and gynecologic cancer with vaginal and sexual-related complaints. Read More ›

In this month’s issue of The Oncology Nurse-APN/PA (TON), we continue our coverage of the news from the recent Oncology Nursing Society (ONS) 39th Annual Congress and the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). Read More ›

Oncology nurses should be aware of the various options for fertility preservation prior to cancer treatment so that they can have discussions with their patients and refer them to fertility specialists when necessary. Read More ›

Skin Toxicity With Targeted Agents
As a result of epidermal growth factor receptor inhibitors, many patients experience rash as an adverse event. Such skin toxicities may lead to bacterial, viral or fungal infections, as well as ocular complications. Read More ›

Deforia Lane, PhD, MT-BC, delivered the final address of the Fourth Annual Conference of the Academy of Oncology Nurse & Patient Navigators. Lane is the Associate Director of the Seidman Cancer Center, and Director of Music Therapy at University Hospitals of Cleveland, Seidman Cancer Center, and Rainbow Babies & Children’s Hospital. Read More ›

Subsets of patients with colon cancer may benefit from increased surveillance for toxicities associated with adjuvant FOLFOX (leucovorin, fluorouracil, oxaliplatin) treatment, Canadian researchers suggest, based on their detailed analysis of the toxicity profile of this common regimen and their identification of factors that predict toxicity. They presented their findings at the 2014 Gastrointestinal Cancers Symposium, held January 16-18, in San Francisco, California. Read More ›

Data from a large population of patients with multiple myeloma receiving zoledronic acid infusions indicate that osteonecrosis of the jaw (ONJ) remains a significant complication, especially for patients who receive it for prolonged periods, investigators from Greece reported at the 2013 American Society of Hematology annual meeting. Read More ›

NEPA, a fixed-dose combination of netupitant and palonosetron, proved more effective than palonosetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) in a large multinational study of 1455 patients, according to data presented at the 2013 San Antonio Breast Cancer Symposium. Read More ›

Page 5 of 13

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: